Themis Bioscience is a start-up biotechnology company.
Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 18, 2019 | Series D | €40M | 1 | — | — | Detail |